Testing in-situ formed nanofibers for inhibiting metastatic osteosarcoma (mOS) in murine models

Information

  • Research Project
  • 10290529
  • ApplicationId
    10290529
  • Core Project Number
    R03CA262920
  • Full Project Number
    1R03CA262920-01
  • Serial Number
    262920
  • FOA Number
    PAR-20-052
  • Sub Project Id
  • Project Start Date
    7/9/2021 - 3 years ago
  • Project End Date
    6/30/2023 - a year ago
  • Program Officer Name
    FU, YALI
  • Budget Start Date
    7/9/2021 - 3 years ago
  • Budget End Date
    6/30/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    01
  • Suffix
  • Award Notice Date
    7/9/2021 - 3 years ago
Organizations

Testing in-situ formed nanofibers for inhibiting metastatic osteosarcoma (mOS) in murine models

Abstract The treatment outcome of metastatic osteosarcoma (mOS) remains poor and has not improved for over four decades. Thus, developing novel approaches for treating mOS is urgently needed. We unexpectedly find that enzyme-instructed self-assembly (EISA) is able to form nanofibers (NFs) inside the nuclei of mOS cells and selectively killing the mOS cells in cell culture. This proposed pilot study is to test the in-situ formed NFs for inhibiting tumor growth in murine models. This research program will focus on two specific aims: Aim 1, synthesis and characterization of the molecules for EISA in the nuclei of mOS cells; Aim 2, pilot study of the EISA substrates for inhibiting mOS tumors in clinically relevant murine models. The rigor of prior research is that (i) overexpression of alkaline phosphatase (ALP) is a key feature of mOS, (ii) our preliminary results show that EISA forms NFs inside nuclei to selectively inhibit mOS cells, and (iii) EISA forms cytosolic NFs to selectively inhibit mOS tumors in vivo. The innovation is to target the nuclei of mOS cells by EISA. The success of the proposed studies will contribute to the development of new molecular targeting agents for selectively killing mOS, which may ultimately lead to breakthrough in treating mOS.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R03
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
    50000
  • Indirect Cost Amount
    31250
  • Total Cost
    81250
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    395
  • Ed Inst. Type
    SCHOOLS OF ARTS AND SCIENCES
  • Funding ICs
    NCI:81250\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    BRANDEIS UNIVERSITY
  • Organization Department
    CHEMISTRY
  • Organization DUNS
    616845814
  • Organization City
    WALTHAM
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    024532728
  • Organization District
    UNITED STATES